Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03108378 · ClinicalTrials.gov registry record
Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With Control
A clinical trial, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- 28
- Enrollment target
NCT03108378 is a clinical trial that has completed, run by Bracco Diagnostics. The registered enrollment target is 28 participants.
The verdict
NCT03108378 has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
Subjects must be scheduled to undergo an orthopedic surgical procedure. Subjects in the non-control group must have previously received an MRI with MultiHance or ProHance with at least 1 month between the last administration and the scheduled surgery. Subjects who have never received MultiHance or ProHance or any other gadolinium agent will also be enrolled. Subjects must have a test of their kidney function (SCr) at the time of the last MRI examination or at the time of enrollment if they never received gadolinium. A sample of bone and skin will be collected from the scheduled surgery and tested for the amount of gadolinium. An additional sample of skin will be collected for testing the presence of nephrogenic systemic fibrosis (NSF).
Interventions
- PROCEDURE Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2014-10 |
| Est. Completion | 2019-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03108378
The ClinicalTrials.gov registry entry for NCT03108378 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Surgery is the first listed.
NCT03108378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03108378 about?
NCT03108378 is a clinical study titled "Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With Control". Subjects must be scheduled to undergo an orthopedic surgical procedure. Subjects in the non-control group must have previously received an MRI with MultiHance or ProHance with at least 1 month between the last administration and the scheduled surgery. Subjects who have never received MultiHance or P...
What is the current status of trial NCT03108378?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2014-10. Estimated completion is 2019-12.
What interventions are being tested in trial NCT03108378?
The interventions under investigation include: Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT03108378?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.